|
pubmed:abstractText |
The use of androgen deprivation therapy for prostate cancer has been increasing, even in settings for which there is weak or no evidence of efficacy. This pattern suggests that factors other than the typical patient and tumor characteristics may be driving its use. We assessed the importance of the physician as a determinant of the use of androgen deprivation therapy in prostate cancer in a population-based, retrospective cohort study using the Surveillance, Epidemiology and End-Results-Medicare linked database.
|
|
pubmed:affiliation |
Department of Internal Medicine, University of Texas Medical Branch, John Sealy Annex 4.200, 301 University Blvd., Galveston, TX 77555-0562, USA. vbshahin@utmb.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, N.I.H., Extramural
|
